Bioblast Pharma regains compliance with Nasdaq listing rule
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback
Infographic: The Big Picture 2023 Sustainability Outlook
The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism
Bioblast Pharma Ltd. regained compliance with a Nasdaq listing rule that requires the company to maintain a minimum bid price of $1 per share.
After 10 consecutive business days following the company's 1-for-5 reverse stock split on Sept. 25, the closing bid price for Bioblast's ordinary shares was $1 per share or greater, the company said in a filing.
